Synergia Medical’s NAO.VNS™ device, implanted in five patients in Belgium, has met its primary safety endpoint in the AURORA first-in-human clinical study. The implantable device, designed to treat drug-resistant epilepsy (DRE) via vagus nerve stimulation (VNS), demonstrated no serious adverse events or device failures over three months. This next-generation neuromodulation platform eliminates metal components found in traditional devices, resulting in full compatibility with MRI and other electromagnetic interference (EMI) sources like electrosurgery and defibrillators.
This successful initial trial is a critical step forward for patients with DRE, a debilitating condition for which current treatment options are often inadequate. The NAO.VNS™ device offers several potential advantages over existing VNS technology. Uninterrupted treatment during MRI scans allows physicians to monitor brain activity and tailor therapy in real-time. Moreover, the device’s innovative battery technology, requiring only one minute of daily charging for an estimated 15-year lifespan, significantly improves patient convenience and reduces the need for repeat surgeries for battery replacement.
Technically, the device has demonstrated robust performance and safety. Three months post-implantation, no adverse events or device malfunctions were reported. From a patient perspective, initial feedback highlights the convenience of the fast-charging, long-lasting battery. Strategically, Synergia Medical is now poised to initiate pivotal FDA and CE trials, paving the way for potential market approval.
This positive early data suggests a promising future for the NAO.VNS™ device and for patients with DRE. Successful completion of pivotal trials could lead to a paradigm shift in neuromodulation, offering a safer, more convenient, and potentially more effective treatment option. The ability to conduct real-time MRI-guided therapy adjustments could significantly improve treatment outcomes and personalize care for individuals struggling with DRE.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
